Slate Run Pharmaceuticals Recalls Eptifibatide Injection Due to Labeling Error
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Slate Run Pharmaceuticals has issued a voluntary recall for Eptifibatide Injection (75 mg/100 mL) due to a labeling error that misidentifies the product's intended administration method.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Slate Run Pharmaceuticals has initiated a voluntary recall of Eptifibatide Injection, 75 mg/100 mL, due to a labeling discrepancy on the product's carton. The packaging incorrectly states the vial is for "weight-adjusted bolus dosing," while the FDA-approved statement should read "weight-adjusted infusion."
Which Products Are Affected
The recall affects all lots within expiry of the following products:
- Product Name: Eptifibatide Injection, 75 mg/100 mL vial
- Slate Run Carton Label: NDC 70436-027-80 (UPC: 0370436027804)
- ProRx Carton Label: NDC 70436-163-80 (UPC: 0370436163809)
- Manufacturer: Hainan Poly Pharm. Co., Ltd.
- Distributor: Slate Run Pharmaceuticals, LLC
This recall applies to distribution nationwide within the United States.
What You Should Do
Healthcare providers and facilities should immediately check their inventory for the affected NDC numbers listed above. If the mislabeled product is found, contact Slate Run Pharmaceuticals for instructions regarding the return or replacement of the vials. Consumers with questions regarding this recall can contact the firm at their Columbus, Ohio headquarters.
Why This Matters
This is classified as a Class III recall, which indicates that the use of or exposure to the mislabeled product is not likely to cause adverse health consequences, but the labeling error represents a regulatory violation.
Source
Information provided by the FDA under Recall Number D-0343-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.